May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal vs. Subtenons Delivery of Avastin
Author Affiliations & Notes
  • Z. Hoffelt
    University of Missouri-Columbia, Columbia, Missouri
  • D. Hainsworth
    University of Missouri-Columbia, Columbia, Missouri
  • B. Privett
    University of Missouri-Columbia, Columbia, Missouri
  • Footnotes
    Commercial Relationships  Z. Hoffelt, None; D. Hainsworth, None; B. Privett, None.
  • Footnotes
    Support  Supported in part by an unrestricted grant from Research to Prevent Blindness, Inc., New York, NY.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1826. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z. Hoffelt, D. Hainsworth, B. Privett; Intravitreal vs. Subtenons Delivery of Avastin. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1826. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Bevacizumab (Avastin) has shown great promise in the treatment of choroidal neovascularization in macular degeneration. Currently, bevacizumab is delivered to the eye via an intravitreal injection. This type of injection poses many risks including endophthalmitis, hemorrhage and retinal detachment. We examined sub-tenon injection as an alternative delivery method for bevacizumab in a rabbit model to determine whether this less invasive delivery route would provide comparable intravitreal drug concentrations.

Methods: : New Zealand White rabbits were used for this study.Group 1) 1.25mg of bevacizumab was injected intravitreally in 9 rabbits. Three rabbits were sacrificed at 1, 6, and 24 hours after injection.Group 2) 12.5mg of bevacizumab was injected in the sub-tenon space in 12 rabbits. Three rabbits were sacrificed at 6, 24, 48 and 96 hours after injection.Intravitreal concentration of bevacizumab was determined for all eyes by high-performance liquid chromatography.

Results: : Average vitreous bevacizumab concentrations (microgram/ml) following intravitreal injection were 79.5 at one hour; 113.1 at 6 hours; and 158.9 at 24 hours.Average vitreous bevacizumab concentrations (micrograms/ml) following sub-tenon injections were 3.1 at 6 hours; 1.9 at 24 hours; 5.0 at 48 hours and 11.8 at 96 hours.

Conclusions: : Bevacizumab injected into the sub-tenon space results in measurable drug levels in the vitreous. These levels are less than the levels achieved through direct intravitreal injection. Whether these levels are adequate to inhibit neovascular membranes is unknown.

Keywords: vascular endothelial growth factor • injection • age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.